Journal of Clinical Oncology (JCO) Podcast
The Journal of Clinical Oncology Podcast features analyses and discussions on the latest findings from ASCO's flagship journal. Host Dr. Davide Soldato facilitates interviews and scholarly discourse on impactful published research. The podcast aims to empower clinicians to integrate cutting-edge evidence into practice. It also includes a series where fellows summarize top articles from the journal.
Episodes
pCR Rates and Predictors With THP in HER2-Positive Breast Cancer: EA1181/CompassHER2 pCR
What pCR rates can be achieved with neoadjuvant THP, and which patients are most likely to respond? Host Dr. Davide Soldato interviews Dr. Nadine Tung on her article, "Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2-Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR." They examine differences in pCR by estrogen rec
JCO Article Insights: Long-Term Follow-Up of Weekly Cisplatin + RT in Postoperative HNC
Host Dr. Jake New interviews Dr. Makoto Tahara about the JCO article "Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer." They discuss clinical considerations for individualizing treatment schedules and impact of treatment schedule on toxicity and patient quality of life. LI
Dexrazoxane and Long-Term Cardiac Function After Doxorubicin: Insights From COG ALTE11C2
How does dexrazoxane affect left ventricular function over time after doxorubicin treatment for childhood cancer? Host Dr. Davide Soldato sits down with Dr. Erin Mobley and Dr. Eric Chow to discuss their article, "Longitudinal Change in Cardiac Function After Doxorubicin and Dexrazoxane: A Report from COG ALTE11C2." They examine the longitudinal echocardiographic findings, the durability of cardio
Bladder Adjuvant RadioTherapy (BART) RCT for High Risk MIBC
Guest Dr. Vedang Murthy and host Davide Soldato discuss JCO article, "Bladder Adjuvant Radiotherapy: Phase III Multicenter Randomized Controlled Trial of Adjuvant Radiotherapy or Observation for Postcystectomy Muscle-Invasive Bladder Cancer" and delve into trial design, results, clinical implications, and future directions in bladder cancer treatment. LINK TO FULL TRANSCRIPT
JCO Article Insights: Duvelisib in Patients with Relapsed or Refractory PTCL
In this episode of JCO Article Insights, host Ash Gurumurthi summarizes the article "Duvelisib Induces Deep Responses in Peripheral T-Cell Lymphoma: Final Results of the Phase II PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma," by Mehta-Shah and colleagues. LINK TO FULL TRANSCRIPT
Effectiveness of a Virtual Tobacco Treatment for Cancer Patients
Guests Dr. Elise Park, Dr. Jamie Ostrov and host Dr. Davide Soldato discuss JCO article "Virtual Sustained Tobacco Treatment for Cancer Patients: A Randomized Controlled Trial (ECOG-ACRIN: EAQ171CD) within the NCI Community Oncology Research Program (NCORP)" and their groundbreaking trial on virtual tobacco cessation treatment for cancer patients in community settings. LINK TO FULL TRANSCRIPT
Phase 2 Study of Multi-Cancer Detection from Breath Samples
Guests Akash Kulgod and Dr. Sanjeev Kulgod and host Dr. Davide Soldato discuss JCO article, "Canine Olfaction Combined with Bayesian Modeling for Multi Cancer Detection from Breath Samples, a Phase 2 Study in India" and the innovative breath-based canine olfaction for multi-cancer detection in low-resource settings, the Bayesian modeling integration, and future prospects for scalable, non-invasive
JCO at ASCO 2026: Individualized Neoantigen Therapy Plus Pembrolizumab in Melanoma
JCO Editorial Fellow Dr. Ash Gurumurthi and JCO Associate Editor Dr. Grant McArthur discuss the ASCO 2026 Simultaneous Publication paper "Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase 2b KEYNOTE-942 Study." LINK TO FULL TRANSCRIPT
JCO at ASCO 2026: Pemigatinib Phase 3 FIGHT-302 Trial in Cholangiocarcinoma
JCO Podcast host Dr. Davide Soldato and JCO Associate Editor Dr. Dr. Eileen M. O'Reilly discuss the ASCO 2026 Simultaneous Publication paper "Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase 3 FIGHT-302 Trial." LINK TO FULL TRANSCRIPT
JCO at ASCO 2026: Individual Patient Pooled Analysis of Low-Dose Tamoxifen in DCIS
JCO Editorial Fellow Dr. Yuvanesh Vedaraju and JCO Associate Editor Dr. Kathy Miller discuss the ASCO 2026 Simultaneous Publication paper "Low-Dose Tamoxifen in Non-Invasive Breast Neoplasia: Long-Term Results from an Individual Participant Data Pooled Analysis." LINK TO FULL TRANSCRIPT
JCO at ASCO 2026: Neoadjuvant Sacituzumab in MIBC
JCO Editorial Fellow Dr. Jake New and JCO Associate Editor Dr. Umang Swami discuss the ASCO 2026 Simultaneous Publication paper "Neoadjuvant Sacituzumab Govitecan in Patients with Muscle-Invasive Bladder Cancer: Primary Results of SURE-01 Trial." LINK TO FULL TRANSCRIPT
JCO at ASCO 2026: Intravesical Recombinant BCG with Chemo-Immunotherapy in MIBC
JCO Editorial Fellow Dr. Jake New and JCO Associate Editor Dr. Andrea Necchi discuss the ASCO 2026 Simultaneous Publication paper "Addition of Intravesical Recombinant BCG to Perioperative Chemo-Immunotherapy in Muscle-Invasive Bladder Cancer: Primary Analysis of the Single Arm Phase 2 Trial SAKK 06/19." LINK TO FULL TRANSCRIPT
Adjuvant Durvalumab and the Future of Early-Stage NSCLC
Guest Dr. Glenwood Goss and host Dr. Davide Soldato discuss JCO article, "Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung Cancer" and the implications of minimal residual disease, results regarding the efficacy of immunotherapy in the adjuvant setting, and the evolving strategies for patient care in lung cancer treatment. LINK TO FULL TRANSCRIPT
JCO Article Insights: LEAP-010 Study in Recurrent/Metastatic Head and Neck Cancer
Host Jake New summarizes and offers insights into the JCO article by Licitra et al., "Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study." LINK TO FULL TRANSCRIPT
Infections in Two Diet Strategies in HSCT and Leukemia Patients
Guest Dr. John Wingard and host Dr. Davide Soldato discuss JCO article, "Randomized Non-inferiority Trial of a Liberalized Diet Versus the Neutropenic Diet in Hematopoietic Stem Cell Transplant and Acute Leukemia Patients," the reason behind the trial, its design, methodology, results, and the implications for future dietary approaches in hematology. LINK TO FULL TRANSCRIPT
JCO Article Insights: ctDNA in DLBCL - Ready for Prime Time?
In this episode of JCO Article Insights, host Dr. Ash Gurumurthi summarizes JCO articles, "Phased Variant–Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study" and " Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma" TRANSCRIPT Ash G
The CISTO Study: Radical Cystectomy or Bladder-Sparing Therapy for Recurrent NMIBC
Guest Dr. John Gore and host Dr. Davide Soldato discuss JCO article, "12-Month Results from the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent Non-Muscle Invasive Bladder Cancer," which compares radical cystectomy and bladder sparing therapy for patients with recurrent high-grade non-muscle invasive bladder cancer. Dr. Gore and Dr. Soldato focus on the study'
JCO Article Insights: Atezolizumab, Bevacizumab, and Non-Platinum Chemotherapy for PROC
In this episode of JCO Article Insights, host Dr. Melis Canturk summarizes the article, "Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial," by Harter et al. TRANSCRIPT Melis Canturk: Hello, and welcome to the JCO Article Insight. I'm your host, Melis Canturk, and today we w
JCO Article Insights: Ribociclib Plus Letrozole in Recurrent LGSOC: GOG 3026
In this episode of JCO Article Insights, host Dr. Melis Canturk summarizes the article, "Phase 2 Trial of Ribociclib plus Letrozole in Women with Recurrent Low-Grade Serous Cancer of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial," by Slomovitz et al. TRANSCRIPT Melis Canturk: Hello, and welcome to JCO Article Insights. I'm your host, Melis Canturk, and today we will be discuss
NCI Working Group on Biochemically Recurrent Prostate Cancer
Host Dr. Davide Soldato and guests Dr. David Einstein and Dr. Ravi Madan discuss JCO article, "National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations," underscoring the need for a consensus on clinical trial designs implementing novel endpoints in this population and the importance of PSA doubling time as a prognostic factor, with
Association Between EOL SACT and Healthcare Utilization
Host Dr. Davide Soldato and guests Dr. Kerin Adelson and Dr. Maureen Canavan discuss JCO article "Association Between Systemic Anticancer Therapy Administration Near the End of Life with Health Care and Hospice Utilization in Older Adults: A SEER Medicare Analysis of End-of-Life Care Quality," highlighting adverse outcomes for patients who receive any type of systemic anticancer therapy(SACT) at E
Milan Consensus Endpoints for Bladder Preservation in MIBC
Guests Dr. Andrea Necchi, Dr. Ashish Kamat and host Dr. Davide Soldato discuss JCO article "End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer," focusing on the evolving treatment landscape of MIBC (muscle-invasive bladder cancer) and the need to properly design novel trials investigating non-operative management while including
JCO at 2025 ASH: Pirtobrutinib in Untreated CLL
JCO Editor-in-Chief Dr. Jonathan Friedberg is joined by colleagues Dr. Jennifer Woyach, Dr. Wojciech Jurczak, and Dr. Matthew Davids to discuss simultaneous publications presented at ASH 2025 on pertibrutinib, a new upfront treatment option for patients with chronic lymphocytic leukemia. TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Dr. Jonathan Friedberg:
JCO at ASH 2025: A New Validated Staging System for AL Amyloidosis: AL-ISS
JCO Editorial Fellow Peter Li and author Dr. Jahanzaib Khwaja discuss the ASH 2025 Simultaneous Publication article, "A New Validated Staging System for AL Amyloidosis With Stage lllC Defining Ultra-Poor Risk: AL International Staging System." TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Dr. Peter Li: Welcome to this episode of JCO Article Insights. I am D
JCO Article Insights: Simultaneous Durvalumab and CRT in Unresectable Stage III NSCLC
In this episode of JCO Article Insights, host Dr. Ece Cali Daylan interviews author Dr. Jeffrey Bradley about the article, "Simultaneous Durvalumab and Chemoradiotherapy in Unresectable Stage III Non–Small Cell Lung Cancer" by Bradley, et al published October 13, 2025. TRANSCRIPT Dr. Ece Cali: Welcome to this episode of JCO Article Insights. This is Dr. Ece Cali, JCO Editorial Fellow. Today I'm jo
Health Outcomes in Older Childhood Cancer Survivors
Guest Dr. Rusha Bhandari and host Dr. Davide Soldato discuss JCO article "Health Outcomes Beyond Age 50 Years in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study, " with a particular focus on mortality data, development of secondary malignancies and the importance of education for both patients and healthcare providers regarding long-term follow-up and care. TRANSC
Long-Term Remission After Cilta-cel in Patients With RRMM
Guest Dr. Sundar Jagannath and host Dr. Davide Soldato discuss JCO article "Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma," and the efficacy of CAR-T cell therapy in patients with heavily pretreated RRMM (relapsed/refractory multiple myeloma). TRANSCRIPT Dr. Davide Soldato: Hello and we
JCO Article Insights: Xevinapant Plus Chemoradiotherapy in Unresected LA SCCHN
In this episode of JCO Article Insights, host Dr. Lauren Shih summarizes the article, "Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study" by Bourhis, et al published September 03, 2025 TRANSCRIPT
Income Among Adolescents and Young Adults Surviving Cancer
Host Dr. Shannon Westin and guest Dr. Giancarlo Di Guiseppe discuss the JCO article "Long-Term Dynamic Financial Impacts Among Adolescents and Young Adults With Cancer: A Longitudinal Matched-Cohort Study" TRANSCRIPT The guest on this podcast episode has no disclosures to declare. Dr. Shannon Westin: Hi everybody and welcome to another episode of JCO After Hours, the podcast where we go in dep
JCO Article Insights: Phase I DLL3/CD3 T-Cell Engager in DLL3-Positive SCLC or NECs
In this JCO Article Insights episode, Dr. Ece Cal interviews Dr. Martin Wermke, author of the JCO article, "Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas." TRANSCRIPT The disclosures for guests on this podcast can be found in the transcript.
TTFields in Locally Advanced Pancreatic Adenocarcinoma
Host Dr. Shannon Westin and guest Dr. Hani Babiker discuss the JCO article "Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study." TRANSCRIPT TTFields in Locally Advanced Pancreatic Adenocarcinoma Dr. Shannon Westin: Hello everyone, and welcome to another episode of JCO After Hours, th
JCO at WCLC: Multinational Pivotal Study of Sunvozertinib in Exon20ins NSCLC
JCO fellow Dr. Ece Cali speaks with JCO Associate Editor Dr. Thomas E. Stinchcombe to discuss the JCO article "Phase 2 Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small-Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)", that was simultaneously released at the IASLC 2025 World Conference on Lung Cancer. TRANSCRIPT Dr. Ece Cali:
Racial and Ethnic Disparities Among Medicare Beneficiaries
Host Davide Soldato and guest Dr. John K. Lin discuss the JCO article "Racial and Ethnic Disparities Along the Treatment Cascade Among Medicare Fee-For-Service Beneficiaries with Metastatic Breast, Colorectal, Lung, and Prostate Cancer." TRANSCRIPT The guest on this podcast episode has no disclosures to declare. Dr. Davide Soldato: Hello, and welcome to JCO After Hours, the podcast where we si
JCO Article Insights: Lymph Node Dissection for Lung Cancer
In this JCO Article Insights episode, Dr. Joseph Matthew interviews authors Dr. Yang Zhang and Dr. Haiquan Chen about their recently published JCO article, "Phase III Study of Mediastinal Lymph Node Dissection for Ground Glass Opacity–Dominant Lung Adenocarcinoma" TRANSCRIPT Joseph Mathew: Welcome to the Journal of Clinical Oncology Article Insights episode for the August issue of the JCO. This i
JCO Article Insights: IMS-IMWG Consensus on High-Risk Multiple Myeloma
In this JCO Article Insights episode, Michael Hughes summarizes "International Myeloma Society and International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma" by Avet-Loiseau et al. published on June 09, 2025 along with an interview with author Dr Nikhil C. Munshi, MD. TRANSCRIPT Michael Hughes: Welcome to this episode of JCO Article Insights. Thi
JCO Article Insights: Pooled Taletrectinib Efficacy and Safety
In this JCO Article Insights episode, host Peter Li summarizes "Taletrectinib in ROS1-Mutated Non–Small Cell Lung Cancer: TRUST" by Pérol et al, published April 03, 2025, followed by an interview with first author, Dr Maurice Pérol. TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Dr. Peter Li: Welcome to this episode of JCO Article Insights. I am Dr. Peter
JCO at ASCO Annual Meeting: Neoadjuvant Osimertinib for Resectable EGFR-Mutated NSCLC
JCO Editorial Fellow Dr. Ece Cali Daylan and JCO Associate Editor Dr. Thomas Stinchcombe discuss the ASCO 2025 Simultaneous Publication paper "Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small-Cell Lung Cancer." Transcript The guest on this podcast episode has no disclosures to declare. Dr. Ece Cali: Hello, and welcome to our 2025 ASCO Annual Meeting series, where we cover some of th
JCO at ASCO Annual Meeting: Use of Low-Value Cancer Treatments in Medicare
JCO Editorial Fellow Dr. Lauren Shih and JCO Associate Editor Dr. Stephanie Wheeler discuss the ASCO 25 Simultaneous Publication paper "Use of Low-Value Cancer Treatments in Medicare Advantage Versus Traditional Medicare." Transcript The guest on this podcast episode has no disclosures to declare. Dr. Lauren Shih: Hello, and welcome to our 2025 ASCO annual meeting series where we cover some of th
JCO at ASCO Annual Meeting: Avelumab Plus Cetuximab vs. Avelumab in Advanced cSCC
JCO Editorial Fellow Dr. Ece Cali Daylan and JCO Associate Editor Dr. Grant McArthur discuss the ASCO 2025 Simultaneous Publication paper "A Phase II (Alliance A091802) Randomized Trial of Avelumab Plus Cetuximab vs. Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma (cSCC)." Transcript The guest on this podcast episode has no disclosures to declare. Dr. Ece Cali: Hello, and welcome to
JCO at ASCO Annual Meeting: TTFields in Locally Advanced Pancreatic Adenocarcinoma
JCO Editorial Fellow Peter Li and JCO Associate Editor Eileen O'Reilly discuss the ASCO 25 Simultaneous Publication paper "Tumor-Treating Fields with Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal, Phase 3 PANOVA-3 Study." Transcript The guest on this podcast episode has no disclosures to declare. Dr. Peter Li: Hello, and welcome to
JCO at ASCO Annual Meeting: Lenvatinib Plus Pembrolizumab and Chemotherapy in Gastric Cancer
JCO Editorial Fellow Dr. Peter Li and JCO Associate Editor Dr. Andrew Ko discuss the ASCO 25 Simultaneous Publication paper "Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III Randomized LEAP-015 Study." Transcript The guest on this podcast episode has no disclosures to declare. Dr. Peter Li: Hello, everyone, an
JCO Article Insights: Double Hit Myeloma Correlates With Adverse Patient Outcome
In this JCO Article Insights episode, host Michael Hughes summarizes "Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma" by Kaiser et al, published February 18, 2025, followed by an interview with JCO Associate Editor Suzanne Lentzsch. Transcript Michael Hughes: Welcome to this episode of JCO Article Insights. This is Micha
Pembrolizumab and Bevacizumab for Melanoma Brain Metastases
Host Dr. Davide Soldato and guest Dr. Harriet Kluger discuss the JCO article "Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases." Transcript The guest on this podcast episode has no disclosures to declare. Dr. Davide Soldato Hello and welcome to JCO After Hours, the podcast where we sit down with authors from some of the latest articles publi
JCO Article Insights: ESPAC4 Long-Term Follow-Up in Pancreatic Cancer
In this JCO Article Insights episode, host Joseph Mathew summaries Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial, by Palmer, et al published December 5, 2024. Transcript Joseph Mathew: Hello and welcome to the Journal of Clinical Oncology Article Insights. I'm your host, Joseph Mathew, and today we will be discussing the article "Long-Term Surviv
Longitudinal Results from the Nationwide Just ASK Initiative to Promote Routine Smoking Assessment
Host Dr. Davide Soldato and guests Dr. Jessica Burris discuss the article "Longitudinal Results from the Nationwide Just ASK Initiative to Promote Routine Smoking Assessment in American College of Surgeons Accredited Cancer Programs" and how persistent smoking following cancer diagnosis causes adverse outcomes while smoking cessation can improve survival. TRANSCRIPT The guest on this podcast epis
JCO Article Insights: Smoking Assessment
In this JCO Article Insights episode, Lauren Shih summaries "Longitudinal Results From the Nationwide Just ASK Initiative to Promote Routine Smoking Assessment in American College of Surgeons–Accredited Cancer Programs" by Jessica L. Burris, et al published November 19, 2024. Come back for the next episode where JCO After Hours host, Dr. Davide Soldato interviews the author of the JCO article
Botensilimab Plus Balstilimab in Advanced Sarcomas
Dr. Shannon Westin and her guest, Dr. Breelyn Wilky, discuss the JCO article, ""Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas." TRANSCRIPT Shannon Westin: Hello, everyone, and welcome to another episode of JCO After Hours, the podcast where we get in depth on res
JCO Article Insights: Long-Term Outcome of Neoadjuvant Chemotherapy for Rectal Cancer
In this JCO Article Insights episode, Peter Li summarizes "Neoadjuvant Modified Infusional Fluorouracil, Leucovorin, and Oxaliplatin With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Updated Results of the FOWARC Study After a Median Follow-Up of 10 Years," by Dr. Jianwei Zhang et al. published on December 13, 2024. TRANSCRIPT Peter Li: Hello and we
High Omega-3, Low Omega-6 Diet with Fish Oil and Prostate Cancer
Host Dr. Shannon Westin and guests Dr. Bill Aronson discuss the article "High Omega-3, Low Omega-6 Diet With Fish Oil for Men With Prostate Cancer on Active Surveillance: The CAPFISH-3 Randomized Clinical Trial" and how Omega-6 are predominant in the American diet while the study significantly lowered the intake of Omega- 6 fats. TRANSCRIPT Dr. Shannon Westin: Hello everyone and welcome to anot
JCO Article Insights: TROPION-Lung01 Dato-DXd in NSCLC
In this JCO Article Insights episode, Ece Cali summarizes findings from the JCO article, "Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study." TRANSCRIPT Ece Cali: Hello and welcome to the JCO Article Insights. I'm your host Ece Cali and today we will be discussing the Journal
Air Pollution and Breast Cancer Incidence
Host Dr. Davide Soldato and his guests Dr. Ann Wu and Dr. Alexa White discuss the article "Air Pollution and Breast Cancer Incidence in the Multiethnic Cohort Study" and the editorial "Growing Evidence for the Role of Air Pollution in Breast Cancer Development" TRANSCRIPT The guests on this podcast episode have no disclosures to declare. Dr. Davide Soldato: Hello and welcome to JCO After Ho
JCO Article Insights: Adoption of Capivasertib in Metastatic Hormone Receptor–Positive, HER2-Negative Breast Cancer – Efficacy, Toxicity and Treatment Sequencing
In this JCO Article Insights episode, Giselle de Souza Carvalho provides a summary on "Navigating Treatment Pathways in Metastatic Hormone Receptor–Positive, HER2-Negative Breast Cancer: Optimizing Second-Line Endocrine and Targeted Therapies" by Bhardwarj, et al and "US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor–Positive, Human Epidermal Gro
Overcoming Barriers to Make Patient-Partnered Research a Reality
Host Dr. Davide Soldato and guests Dr. Suzanne George and Liz Salmi discuss their JCO article "Overcoming Systemic Barriers to Make Patient-Partnered Research a Reality" TRANSCRIPT TO COME Dr. Davide Soldato: Hello and welcome to JCO's After Hours, the podcast where we sit down with authors from some of the latest articles published in the Journal of Clinical Oncology. I am your host, Dr. Davide
JCO Article Insights: Nivolumab + Relatlimab v Nivolumab + Ipilimumab in Melanoma
In this JCO Article Insights episode, Rohit Singh provides a summary on "First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data", by Long et al, published in the November issue of the Journal of Clinical Oncology. The article provides insights into the use of the two dual immune
Quality of Treatment Selection
Host Dr. Davide Soldato and Dr. Aaron Mitchell discuss the JCO article "Quality of Treatment Selection for Medicare Beneficiaries With Cancer" TRANSCRIPT Dr. Davide Soldato: Hello and welcome to JCO After Hours, the podcast where we sit down with authors from some of the latest articles published in the Journal of Clinical Oncology. I am your host, Dr. Davide Soldato, medical oncologist at Hospit
JCO Article Insights: HLA-Mismatched Unrelated Donor HCT With PTCy
In this JCO Article Insights episode, Alexandra Rojek provides a summary on "Post-Transplant Cyclophosphamide–Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors" by Schaffer et al published in the Journal of Clinical Oncology July 17th, 2024. TRANSCRIPT Alexandra Rojek: Hello and welcome to JCO Article Insights. I'
Adjuvant Pembrolizumab for High-Risk, dMMR Endometrial Cancer
Dr. Shannon Westin and her guest, Dr. Brian Slomovitz discuss the article "Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy For Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors" recently published in the JCO and presented at the 2024 International Gynecologic Cancer Society. TRANSCRIPT The guest's disclosures can be fo
Combining Response and Toxicity Data to Implement Project Optimus
In this JCO Article Insights episode, Subodh Selukar interviews author Dr. Robert Maki on "Combining Response and Toxicity Data to Implement Project Optimus" by Maki, et al published in the Journal of Clinical Oncology September 11, 2024. TRANSCRIPT Subodh Selukar: Welcome to this episode of JCO Article Insights. This is Subodh Selukar, JCO's editorial fellow. Today, I am interviewing Dr. Robert
CBT-I for Cancer-Related Cognitive Impairment
Host Dr. Davide Soldato and Dr. Shelia Garland discuss the JCO article "Randomized Controlled Trial of Virtually Delivered Cognitive Behavioral Therapy for Insomnia to Address Perceived Cancer-Related Cognitive Impairment in Cancer Survivors." TRANSCRIPT The guest on this podcast episode has no disclosures to declare. Dr. Davide Soldato: Hello and welcome to JCO After Hours, the podcast where
JCO Article Insights: Assisted Reproduction in Breast Cancer Patients
In this episode of JCO Article Insights, Dr. Giselle de Souza Carvalho interviews Dr. Hatem Azim and Dr. Ann partridge on their JCO article "Fertility Preservation and Assisted Reproduction in Patients With Breast Cancer Interrupting Adjuvant Endocrine Therapy to Attempt Pregnancy," TRANSCRIPT Giselle Carvalho: Welcome to the JCO Article Insights episode for the August issue of the Journal of Cl
Multi-Cancer Early Detection Testing for High-Risk Patients
Host Dr. Davide Soldato interviews Dr. Sana Raoof to discuss the JCO article Turning the Knobs on Screening Liquid Biopsies for High-Risk Populations: Potential for Dialing Down Invasive Procedures. TRANSCRIPT Dr. Davide Soldato: Hello, and welcome to JCO After Hours, the podcast where we sit down with others from some of the latest articles published in the Journal of Clinical Oncology. I am yo
JCO Article Insights: Back to the Drawing Board: Overcoming Resistance to PD-1 Blockade
In this episode of JCO Article Insights, Rohit Singh interviews Dr. Ticiana Leal on the editorial, "Back to the Drawing Board: Overcoming Resistance to PD-1 Blockade." TRANSCRIPT The guests' disclosures can be found in the transcript. Dr. Rohit Singh: Hello and welcome to JCO's Article Insights. I am your host Rohit Singh and today we will be discussing the JCO article, "Back to the Drawing Bo
Functional Disability Among US Cancer Survivors
Dr. Shannon Westin and her guest, Dr. Chao Cao, discuss the paper "Prevalence and Cancer-Specific Patterns of Functional Disability Among US Cancer Survivors, 2017-2022" recently published in the JCO. TRANSCRIPT The guest on this podcast episode has no disclosures to declare. Dr. Shannon Westin: Hello, everyone, and welcome to another episode of JCO After Hours, the podcast where we get in depth
CAR T-Cell Therapy for Richter's Transformation
In this JCO Article Insights episode, Alexandra Rojek provides a summary on "Anti-CD19 Chimeric Antigen Receptor T-cell therapy for Richter's Transformation: An International, Multicenter, Retrospective Study by Kittai, et al published in the Journal of Clinical Oncology March 29th, 2024. TRANSCRIPT The guest on this podcast episode has no disclosures to declare. Alexandra Rojek: Hello and we
EAZ171: Predictors of TIPN in Black Women with Breast Cancer
Dr. Shannon Westin and her guest, Dr. Bryan Schneider discuss the article "ECOG-ACRIN EAZ171: Prospective Validation Trial of Germline Predictors of Taxane-induced Peripheral Neuropathy in Black Women with Early Stage Breast Cancer" recently published in the JCO and presented at the 2024 ASCO Annual Meeting. TRANSCRIPT The guest on this podcast episode has no disclosures to declare. Shannon Westi
JCO Article Insights: Final Analysis of the Ro-CHOP Trial
In this JCO Article Insights episode, Alexandra Rojek provides a summary on "Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial" by Camus et al published February 16th, 2024 and the associated editorial writt
Methylphenidate for Fatigue in Advanced Cancer
Dr. Shannon Westin and her guest, Dr. Patrick Stone, discuss the article, Methylphenidate Versus Placebo for Treating Fatigue in People with Advanced Cancer, a Randomized, Double-Blind, Multicenter Placebo-Controlled Trial, recently published in JCO. TRANSCRIPT The guest on this podcast episode has no disclosures to declare. Shannon Westin: Hello, everyone, and welcome to another episode of J
Introducing JCO Oncology Advances with Dr. Jonathan Friedberg and Dr. Pamela Kunz
JCO Editor in Chief, Dr. Jonathan Friedberg interviews Dr. Pamela Kunz, Editor in Chief of the new premier open access journal, JCO Oncology Advances. Dr. Friedberg and Dr. Kunz discuss what is to come from the journal and the benefits of an open access journal. TRANSCRIPT Dr. Jonathan Friedberg: Hello and welcome to another episode of JCO After Hours. I'm your guest host, Jonathan Friedberg,
JCO Article Insights: Atezolizumab Plus Bevacizumab, Chemotherapy in EGFR, ALK NSCLC
In this JCO Article Insights episode, Rohit Singh provides summary on two articles published in the April 10th issue of the Journal of Clinical Oncology. The first article, "Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Mutated Non–Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04)" describes a randomized, open-label, multicenter, phase III
Commonly Held Beliefs About Cancer Survivorship
Dr. Shannon Westin and her guests, Dr. Emily S. Tonorezos and Dr. Michael Halpern, discuss their article, "Myths and Presumptions About Cancer Survivorship" recently published in the JCO. TRANSCRIPT The guests on this podcast episode have no disclosures to declare. Shannon Westin:Hello, everyone, and welcome to another episode of JCO After Hours, the podcast where we go in depth on manuscrip
JCO Article Insights: Long Term Follow Up of the RESORT (E4402) and LYSA Study
In this JCO Article Insights episode, Alexandra Rojek provides a summary on two long term follow studies: "Long-Term Follow-Up of Rituximab Maintenance in Young Patients With Mantle-Cell Lymphoma Included in the LYMA Trial: A LYSA Study" by Sarkozy, et al published on December 18th, 2023 and "Long Term Follow Up of the RESORT Study (E4402): A Randomized Phase III Comparison of Two Different Rituxi
Pembrolizumab in Patients With Advanced Cancers With HTMB
Dr. Shannon Westin and her guests, Dr. Herbert Duvivier and Dr. Richard Schilsky, discuss the paper "Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study" published in the JCO. TRANSCRIPT The guest on this podcast episode has no disclosures to declare. Shannon Westin: Hello, everyone, and welcome to a
JCO Article Insights: Axillary Soft Tissue Involvement and Breast Cancer Prognosis
In this JCO Article Insights episode, Giselle de Souza Carvalho provides a summary on "Pathologic Exploration of the Axillary Soft Tissue Microenvironment and Its Impact on Axillary Management and Breast Cancer Outcomes" by Naoum, et al and "Optimization of Breast Cancer Regional Nodal Management" by Braunstein et al published in the January 10, 2024 issue in Journal of Clinical Oncology. The ori
Omission of Radiotherapy after Breast-Conserving Surgery
Dr. Shannon Westin and her guest, Dr. Reshma Jagsi, discuss the paper "Omission of Radiotherapy After Breast-Conserving Surgery for Women With Breast Cancer With Low Clinical and Genomic Risk: 5-Year Outcomes of IDEA" recently published in the JCO. TRANSCRIPT The guest on this podcast episode has no disclosures to declare. Shannon Westin: Hello, everyone, and welcome to another episode of JCO
Costs of Cancer Prevention in CDH1 Variant Carriers
Dr. Shannon Westin and her guests, Dr. Jeremy Davis and patient advocate Kathryn Carr, discuss the paper "Costs of Cancer Prevention: Physical and Psychosocial Sequelae of Risk-Reducing Total Gastrectomy" recently published and printed in the JCO. TRANSCRIPT Shannon Westin: Hello, everyone, and welcome to another episode of JCO After Hours, the podcast where we get in depth on manuscripts that a
JCO Article Insights: Low and Moderate Grade Adverse Events and the Patient Experience in Clinical Trials
In this JCO Article Insights episode, Subodh Selukar summarized findings from the original article published in the January 2024 JCO issue: "The Importance of Low and Moderate Grade Adverse Events on Patients' Treatment Experience and Treatment Discontinuation" and accompanying editorial "Patient Experience, Adverse Event Reporting, and Clinical Trial Design". The summary provides information rega
Debunking Sex and Disentangling Gender From Oncology
Dr. Shannon Westin and her guest, Dr. Ash Alpert and Spencer Adams, discuss the paper "Debunking Sex and Disentangling Gender From Oncology" recently published in the JCO. TRANSCRIPT The guests on this podcast episode have no disclosures to declare. Shannon Westin: Hello and welcome to JCO After Hours, the podcast where we get in depth on manuscripts published in the Journal of Clinical Oncolo
Germline EGFR Mutations and Familial Lung Cancer
Dr. Shannon Westin and her guests, Dr. Judy Garber and Dr. Geoffrey Oxnard, discuss the paper "Germline EGFR Mutations and Familial Lung Cancer" recently published in the JCO. TRANCRIPT The guest on this podcast episode has no disclosures to declare. Shannon Westin: Hello, and welcome to JCO After Hours, the podcast where we get in-depth on articles that are published in the Journal of Clini
JCO Article Insights: DYPD-Guided Dose Individualization and Survival Outcomes
In this episode of JCO Article Insights, host Dr. Soldato discussed with Dr. Knikman and Dr. Cats the findings of a study that assesses the influence of fluoropyrimidine dosing based on DYPD genotype on both progression-free and overall survival. The article, featured in the December edition of JCO, presents groundbreaking and reassuring data. Furthermore, it highlights emerging research challenge
Negative Impact of Prior Authorization on Patients with Cancer
Dr. Shannon Westin and her guest, Dr. Michael Anne Kyle and Dr. Nancy L. Keating, discuss the paper "Prior Authorization and Association With Delayed or Discontinued Prescription Fills" recently published in the JCO. TRANSCRIPT The guest on this podcast episode has no disclosures to declare. Shannon Westin: Hello, everyone, and welcome to another episode of JCO After Hours, the podcast that g
